AstraZeneca Pharma India Limited — Board Meeting, 30-05-2025: Outcome of Board Meeting

AstraZeneca has announced a board meeting approving the financial results for the quarter and year ended March 31, 2025. Revenue surged 32% YoY to Rs 1716.3 Cr, led by Oncology (Rs 1117.1 Cr) and Biopharmaceuticals (Rs 488.1 Cr). Profit before tax was Rs 253.1 Cr, with post-tax profit at Rs 115.7 Cr after restructuring costs in Biopharmaceuticals. The board proposed a final dividend of Rs 32 per share. The company is boosting its pipeline with new drug approvals and key leadership changes, supporting its innovation-driven momentum.